Supplemental Material for "Increased risk of COVID-19-related hospitalization in patients with hidradenitis suppurativa compared with controls"

Published: 24 May 2022| Version 1 | DOI: 10.17632/wncdz8kdjk.1
Jonathan Koptyev, Andrew Strunk, Amit Garg


Table S1. Patient eligibility flowchart – Page 2 Table S2. Definitions for exposures, outcomes, and covariates – Pages 3-7 Table S3. Risk of hospitalization for COVID-19 in HS patients and control patients – Page 8 Table S4. Demographic and clinical characteristics according to treatment group – Pages 9-10 Table S5. Incidence of COVID-19 hospitalization among hidradenitis suppurativa patients according to use of biologics and traditional immunosuppressives – Page 11 Table S6. Complete demographic and clinical characteristics of patients with HS and controls – Pages 12- 13



Donald and Barbara Zucker School of Medicine at Hofstra/Northwell


Dermatology, Hidradenitis Suppurativa, COVID-19